background
class
drug
rapid
develop
therapeut
treat
emerg
infect
challeng
timelin
need
identifi
compound
desir
efficaci
safeti
pharmacokinet
profil
fulli
human
monoclon
antibodi
mab
provid
attract
method
overcom
mani
hurdl
rapidli
produc
therapeut
emerg
diseas
method
studi
deploy
platform
gener
test
develop
fulli
human
antibodi
zair
ebolaviru
obtain
specif
antiebola
viru
ebov
antibodi
immun
velocimmun
mice
use
human
immunoglobulin
variabl
region
humor
respons
result
antibodi
clone
isol
select
best
neutral
ebov
trigger
bind
studi
negativestain
electron
microscopi
reveal
select
antibodi
bind
nonoverlap
epitop
includ
potenti
new
protect
epitop
target
antibodybas
treatment
combin
singl
dose
cocktail
antibodi
protect
nonhuman
primat
nhp
ebov
diseas
even
diseas
symptom
appar
conclus
antibodi
cocktail
provid
complementari
mechan
action
incorpor
novel
specif
demonstr
highlevel
postexposur
protect
lethal
ebov
diseas
nhp
undergo
test
normal
healthi
volunt
prepar
potenti
use
futur
ebola
epidem
ebola
viru
pandem
west
africa
result
case
death
throughout
guinea
sierra
leon
liberia
http
wwwwhointcsr
diseaseebolaen
despit
ultim
control
zair
ebolaviru
ebov
singlestrand
ribonucl
acid
virus
filovirida
famili
continu
pose
high
risk
caus
epidem
high
mortal
rate
addit
mortal
associ
acut
infect
diseas
sequela
ebov
infect
includ
neurolog
ocular
complic
joint
muscl
pain
viru
persist
mani
month
persist
particularli
concern
public
health
perspect
given
popul
still
immun
naiv
current
approv
therapi
vaccin
treat
prevent
infect
ebov
filovirus
necessit
develop
clinicalgrad
therapeut
main
target
ebov
vaccin
therapeut
antibodi
viru
glycoprotein
gp
current
valid
therapeut
target
virion
surfac
glycoprotein
produc
altern
transcript
gp
gene
solubl
gp
sgp
main
product
glycoprotein
class
fusion
protein
posttransl
cleav
furin
disulphidelink
subunit
form
trimer
heterodim
surfac
virion
infect
cell
host
cellbound
virion
intern
endosom
virus
expos
low
ph
proteolyt
cleavag
gp
reveal
surfac
bind
endosom
receptor
niemannpick
requir
penetr
nucleocapsid
cell
cytoplasm
initi
replic
sgp
readili
detect
sera
infect
anim
patient
play
role
pathogenesi
multipl
line
evid
support
gp
effect
therapeut
target
liveattenu
recombin
vesicular
stomat
viru
rvsv
vaccin
decor
ebov
gp
protect
nonhuman
primat
nhp
ebov
challeng
protect
induc
rvsv
vaccin
correl
develop
gptarget
antibodi
vaccin
use
ring
vaccin
openlabel
clusterrandom
trial
pandem
show
evid
efficaci
safeti
prevent
ebov
diseas
administ
primari
secondari
contact
infect
patient
outbreak
addit
gpspecif
antibodi
isol
survivor
ebov
infect
immun
anim
shown
effect
treat
ebov
diseas
infect
nhp
howev
efficaci
therapeut
antibodi
prepar
like
requir
combin
neutral
nonneutr
antibodi
multipl
mechan
action
includ
antibodi
effector
function
risk
new
filoviru
epidem
call
develop
product
therapeut
rapidli
deploy
date
ebov
antibodi
therapi
develop
either
human
rodentgener
antibodi
isol
antibodi
gene
infect
patient
method
signific
drawback
antibodi
therapeut
also
face
suppli
constraint
due
challeng
product
method
requir
sequenc
revers
engin
lack
manufacturingreadi
cell
line
therebi
prevent
largescal
product
control
test
treatment
ebov
diseas
studi
describ
use
platform
gener
select
test
manufactur
panel
fulli
human
noncrosscompet
monoclon
antibodi
mab
treat
ebov
diseas
mice
encod
fulli
human
antibodi
variabl
region
gene
segment
velocimmun
mice
immun
ebov
gpbind
antibodi
complementari
biolog
properti
identifi
chines
hamster
ovari
cho
isogen
cell
bank
express
mab
individu
made
mab
immedi
manufactur
use
cocktail
mab
revers
sever
diseas
symptom
greatli
promot
surviv
rhesu
macaqu
administ
day
postebov
challeng
late
diseas
cours
anim
model
studi
describ
biolog
properti
antibodi
bind
gp
outcom
test
nhp
model
diseas
cell
human
embryon
kidney
hek
cell
line
obtain
american
type
cultur
collect
atcc
cell
human
hepatocarcinoma
cell
line
obtain
jcrb
cell
bank
grown
high
glucos
dulbecco
modifi
eagl
media
dmem
gibco
contain
vv
fetal
bovin
serum
fb
gibco
lglutamin
antibiot
penicillinstreptomycin
gibco
co
atmospher
vero
monkey
kidney
epitheli
cell
obtain
atcc
grown
minim
essenti
media
corn
supplement
vv
fb
sigma
aldrich
lglutamin
gibco
penicillinstreptomycin
gemini
bio
product
co
atmospher
eesyr
cho
cell
line
deriv
cho
cell
cho
cell
line
obtain
atcc
previous
describ
us
patent
transfect
perform
use
lipofectamin
ltx
plu
reagent
life
technolog
follow
manufactur
instruct
makona
strain
ebov
origin
isol
dr
stephan
gunther
obtain
permiss
dr
guinea
pigadapt
ebov
master
origin
human
serum
specimen
passag
previous
describ
stock
viru
kindli
provid
dr
heinrich
feldman
stock
use
infect
vero
cell
incub
cytopath
effect
observ
supernat
remov
clarifi
frozen
aliquot
viru
stock
count
convent
plaqu
titrat
codonoptim
complementari
deoxyribonucl
acid
dna
sequenc
encod
ebov
gp
makona
strain
genbank
synthes
clone
express
vector
use
standard
method
pwpxldgfp
encod
human
immunodefici
viru
hiv
gag
pol
green
fluoresc
protein
context
hiv
genom
obtain
tronolab
ecol
polytechniqu
de
lausann
switzerland
pckretroluc
describ
solubl
ebov
gp
makona
strain
purchas
sino
biolog
velocimmun
mice
compris
dna
encod
human
immunoglobulin
ig
heavi
kappa
light
chain
variabl
region
mous
constant
region
immun
dna
express
ebov
gp
purifi
ebov
gp
protein
immunogen
use
standard
techniqu
desir
immun
respons
achiev
splenocyt
harvest
splenocyt
fusion
isol
ebov
gpreactiv
b
cell
perform
use
previous
describ
method
potent
antibodi
bind
neutral
signal
select
subsequ
analysi
recombin
antiebov
gp
antibodi
produc
cho
cell
stabl
transfect
pair
express
plasmid
contain
heavi
chain
light
chain
deriv
b
cell
antibodi
purifi
cultur
supernat
protein
affin
chromatographi
clinicalgrad
antibodi
process
via
nonaffin
column
chromatographi
dedic
viru
removalinactiv
step
equilibrium
dissoci
constant
k
valu
interact
antiebov
gp
antibodi
recombin
ebov
gp
protein
determin
via
surfac
plasmon
reson
spr
use
biacor
instrument
ge
healthcar
specif
biacor
kinet
sensorgram
obtain
standard
doublereferenc
procedur
kinet
paramet
obtain
global
fit
data
bind
model
use
biacor
evalu
curvefit
softwar
dissoci
rate
constant
k
determin
fit
chang
bind
respons
dissoci
phase
associ
rate
constant
k
determin
fit
ebov
gp
bind
differ
concentr
k
calcul
ratio
k
k
dissoci
halflif
calcul
bind
antiebov
gp
antibodi
solubl
ebovsgp
determin
use
realtim
labelfre
biolay
interferometri
assay
bli
octet
htx
system
hbsep
octet
buffer
epitop
bin
antiebov
gp
antibodi
determin
use
octet
htx
system
equip
antihi
sensor
pall
fortebio
experi
perform
hbsep
octet
buffer
plate
shake
rpm
data
analysi
perform
use
fortebio
data
analysi
softwar
version
sequenti
bind
ebov
ebov
captur
onto
biacor
amin
coupl
antihi
sensor
surfac
next
first
mab
inject
minut
reach
bind
satur
follow
inject
second
mab
third
mab
condit
bind
sensorgram
referenc
flow
cell
ebov
gp
protein
captur
curv
zero
inject
rel
bind
level
determin
bind
satur
achiev
repeat
antiebov
gp
antibodi
isotyp
control
antibodi
sequenc
permut
realtim
bind
respons
monitor
cours
experi
bind
respons
end
everi
step
measur
data
analyz
use
evalu
softwar
version
antibodi
digest
use
ww
papain
hour
fragment
antigenbind
agent
fab
purifi
use
protein
column
ge
healthcar
follow
size
exclus
chromatographi
increas
column
ge
healthcar
fab
ad
mucinlik
domaincontain
transmembranedelet
ebola
gp
ebov
molar
excess
allow
incub
overnight
complex
subsequ
purifi
use
column
ebola
gp
fab
complex
deposit
thin
carbonco
cu
grid
stain
wv
uranyl
format
imag
collect
automat
use
leginon
tietz
cmo
camera
tecnai
spirit
electron
microscop
oper
kev
magnif
specimen
plane
constant
defocu
appli
imag
process
appion
particl
select
use
dogpick
place
stack
sort
referencefre
class
averag
multivari
statist
analysi
multirefer
align
remov
abhorr
particl
result
particl
substack
submit
iter
stabl
align
cluster
gener
final
set
class
averag
individu
class
averag
use
gener
initi
model
use
refin
raw
particl
enforc
symmetri
gener
final
model
model
imag
manipul
perform
ucsf
chimera
map
segment
fab
core
gp
compon
use
segger
map
align
singl
gp
densiti
gener
map
gener
fab
model
retroviru
particl
pseudotyp
ebov
gp
protein
gener
cotransfect
cell
mix
plasmid
encod
ebov
gp
encod
viru
capsid
protein
pckretroluc
encod
packag
firefli
luciferas
report
gene
control
retroviru
long
termin
repeat
promot
supernat
harvest
hour
posttransfect
clarifi
use
centrifug
concentr
use
lentix
concentr
clontech
aliquot
frozen
control
pseudoparticl
gener
substitut
plasmid
express
ebov
gp
plasmid
encod
vesicular
stomat
viru
gp
vsvg
ebov
zair
viruslik
particl
test
neutral
assay
cell
serial
dilut
antibodi
pm
incub
ebov
gppseudotyp
viru
hour
room
temperatur
rt
ad
cell
brief
cell
detach
use
edta
wash
incub
antibodypseudotyp
viru
mixtur
hour
infect
effici
quantit
luciferas
detect
brightglo
luciferas
assay
promega
san
lui
obispo
ca
luminesc
rel
luminesc
unit
quantifi
victor
plate
reader
perkinelm
waltham
antibodi
analyz
abil
neutral
infecti
ebov
vero
cell
vero
cell
plate
plate
fb
allow
grow
approxim
confluenc
concentr
antibodi
rang
plate
transfer
biosafeti
level
laboratori
complet
infect
assay
ebov
strain
mayinga
kikwit
makona
guinea
pigadapt
mayinga
thaw
dilut
equival
volum
infecti
ebov
ad
well
multipl
infect
plate
incub
hour
incub
period
plate
remov
incub
inactiv
immers
neutralbuff
formalin
place
heatseal
bag
store
overnight
laboratori
plate
wash
time
phosphatebuff
salin
pb
cell
permeabil
rt
triton
pb
minut
deterg
contain
buffer
discard
plate
block
bsa
pb
hour
rt
plate
treat
overnight
antiebov
gp
primari
antibodi
antiebov
gp
antibodi
ibt
bioscienc
dilut
pb
plate
wash
twice
pb
minut
cell
incub
hour
conjug
antimous
secondari
antibodi
secondari
antibodi
discard
plate
wash
twice
pb
minut
plate
incub
hoechst
dye
pb
minut
rt
plate
imag
fluoresc
microscopi
imag
analyz
cell
profil
use
ht
pipelin
avail
upon
request
rate
infect
determin
divid
number
infect
cell
total
number
cell
infect
rate
normal
averag
untreat
cell
infect
rate
normal
infect
rate
rel
infect
express
percentag
infect
versu
antibodi
concentr
analyz
graphpad
prism
softwar
nonlinear
regress
analysi
plaqu
reduct
neutral
prnt
prnt
determin
manual
graph
antibodi
sigmoid
curv
show
inhibit
respect
potenti
antibodi
induc
antibodydepend
cellular
cytotox
adcc
assess
activ
nuclear
factor
activ
tcell
nfat
signal
presenc
ebov
gp
express
target
cell
antiebov
gp
mab
isotyp
control
antibodi
incub
jurkat
effector
cell
obtain
atcc
engin
express
nfatluc
val
jurkat
val
presenc
cell
engin
tetracyclineinduc
ebov
gp
express
gp
neg
control
cell
engin
tetracyclin
transactiv
protein
alon
val
effector
cell
gp
teton
target
cell
plate
ratio
cell
plate
gener
doserespons
curv
individu
antiebov
gp
mab
mab
cocktail
isotyp
control
antibodi
ad
cell
concentr
rang
pm
nm
except
evalu
concentr
rang
nm
plate
incub
co
hour
follow
equilibr
rt
minut
equal
volum
oneglo
luciferas
substrat
ad
well
plate
incub
rt
minut
rel
luminesc
unit
measur
victor
multilabel
plate
reader
valu
analyz
logist
model
doserespons
curv
graphpad
prism
anim
studi
conduct
protocol
approv
appropri
institut
anim
care
use
committe
iacuc
feder
statut
regul
relat
anim
experi
involv
anim
tbri
protocol
adher
us
depart
agricultur
anim
welfar
regul
public
health
servic
polici
human
care
use
laboratori
anim
nation
research
council
guid
care
use
laboratori
anim
polici
establish
tbri
routin
feed
occur
environ
enrich
provid
per
establish
standard
oper
procedur
anim
singli
hous
properli
assess
sign
diseas
allow
accur
determin
food
consumpt
water
intak
fecal
urin
output
necessari
determin
morbid
analges
clinic
sign
diseas
use
use
analges
may
secondari
effect
mask
clinic
sign
infect
would
prevent
evalu
diseas
sever
addit
analges
may
exacerb
clot
issu
may
also
secondari
unintend
consequ
interact
candid
drug
analges
euthanasia
criteria
creat
help
minim
pain
distress
anim
experi
still
allow
time
collect
suffici
data
valid
treatment
regimen
euthanasia
human
perform
anim
met
establish
moribund
criteria
accord
approv
method
american
veterinari
medic
associ
guidelin
euthanasia
anim
usamriid
protocol
hous
feed
environment
enrich
step
minim
suffer
nhp
adher
principl
state
guid
care
use
laboratori
anim
nation
research
council
anim
studi
perform
laboratori
tbri
usamriid
veterinari
staff
blind
treatment
statu
anim
end
studi
efficaci
studi
singl
antibodi
treatment
male
guinea
pig
hartley
strain
week
old
obtain
charl
river
laboratori
wilmington
randomli
assign
treatment
group
anim
per
group
place
laboratori
week
viru
challeng
fed
care
daili
anim
challeng
intraperiton
target
dose
pfu
guinea
pigadapt
ebov
origin
provid
dr
heinrich
feldman
rocki
mountain
laboratori
nation
institut
health
hamilton
mt
day
group
treat
intraperiton
dose
mg
antibodi
per
anim
equival
volum
salin
placebo
control
anim
observ
least
twice
daili
weight
loss
clinic
sign
surviv
anim
sacrif
week
viru
challeng
blood
sampl
collect
day
viru
challeng
sera
isol
store
c
research
conduct
iacucapprov
protocol
complianc
anim
welfar
act
public
health
servic
polici
feder
statut
regul
relat
anim
experi
involv
anim
facil
research
conduct
accredit
associ
assess
accredit
laboratori
anim
care
intern
adher
principl
state
guid
care
use
laboratori
anim
nation
research
council
researchna
adult
rhesu
macaqu
macaca
mulatta
asian
origin
mix
male
femal
obtain
usamriid
coloni
anim
screen
found
neg
filoviru
antibodi
macaqu
equal
balanc
sex
weight
random
code
blind
anim
challeng
intramuscularli
caudal
thigh
target
dose
pfu
ebov
kikwit
phlebotomi
conduct
via
saphen
venipunctur
follow
day
prechalleng
day
challeng
termin
antibodi
treatment
mgkg
administ
singl
bolu
less
ml
approxim
second
groshong
central
venou
cathet
bard
access
system
salt
lake
citi
ut
via
wing
infus
needl
terumo
medic
product
somerset
nj
phlebotomi
andor
treatment
anim
lightli
anesthet
ketamin
vedco
st
joseph
mo
nonhuman
primat
observ
approxim
everi
hour
show
sign
diseas
realtim
telemetri
analysi
perform
detail
previou
brief
nhp
implant
radio
telemetri
devic
konigsberg
instrument
pasadena
ca
monitor
temperatur
activ
throughout
experi
data
acquir
analyz
via
notocordhem
evolut
softwar
version
notocord
inc
newark
nj
challeng
dose
determin
via
plaqu
assay
day
challeng
vero
cell
plate
plate
day
challeng
serial
dilut
challeng
materi
incub
atop
monolay
hour
incub
monolay
overlain
agaros
seakem
agaros
lonza
rockland
solut
week
cell
overlain
neutral
red
incub
overnight
plaqu
count
light
box
follow
day
process
repeat
enumer
anim
viremia
howev
instead
challeng
materi
serum
serial
dilut
plaqu
assay
perform
describ
serum
separ
tube
greiner
bioon
monro
nc
invert
phlebotomi
left
clot
approxim
minut
time
centrifug
rel
centrifug
forc
rcf
minut
rt
serum
pipet
piccolo
gener
chemistri
disk
run
piccolo
point
care
analyz
abaxi
union
citi
ca
tube
invert
hand
appli
sampl
port
advia
siemen
healthcar
palvern
pa
achiev
complet
blood
count
run
whole
blood
advia
sampl
centrifug
rcf
minut
plasma
remov
cell
pellet
edta
plasma
mix
trireag
ls
sigmaaldrich
respect
polymeras
chain
reaction
pcr
perform
describ
previous
eighteen
male
rhesu
macaqu
mulatta
year
old
obtain
covanc
alic
tx
rang
kg
randomli
assign
treatment
group
place
laboratori
day
viru
challeng
acclim
fed
care
daili
anim
challeng
intramuscularli
target
dose
pfu
ebov
kikwit
day
group
treat
intraven
mgkg
antibodi
cocktail
equival
volum
pb
anim
observ
least
twice
daili
weight
loss
clinic
sign
surviv
anim
euthan
week
viru
challeng
blood
sampl
collect
day
day
viru
challeng
plasma
serum
prepar
biochemistri
viremia
analysi
store
c
quantif
viru
load
anim
sera
plaqu
assay
perform
vero
cell
grown
confluenc
plate
inocul
dilut
anim
serum
incub
supernat
replac
eagl
minimum
essenti
medium
contain
agaros
fb
incub
c
week
media
addit
neutral
red
ad
well
addit
incub
c
plaqu
manual
count
goal
rapidli
select
cocktail
noncompet
ebov
gpspecif
fulli
human
mab
possess
divers
biolog
propertiesmechan
action
obtain
velocimmun
mice
immun
dna
construct
encod
gp
protein
andor
recombin
purifi
gp
protein
makona
strain
select
best
therapeut
antibodi
pool
gpspecif
antibodi
obtain
immun
mice
sever
vitro
screen
assay
use
identifi
antibodi
collect
provid
follow
properti
block
entri
ebov
gppseudotyp
particl
suscept
cell
abil
remain
bound
gp
endosom
ph
prevent
interact
intracellular
receptor
membran
fusion
lack
crosscompetit
ensur
antibodi
simultan
bind
gp
bind
sgp
block
potenti
role
ebov
pathogenesi
fc
effector
function
mediat
kill
ebovinfect
cell
immun
cell
previous
suggest
import
protect
facilit
discoveri
antibodi
mediat
latter
activ
screen
undertaken
antibodi
produc
cho
cell
line
select
abil
produc
antibodi
low
level
termin
fucosyl
data
shown
low
fucosyl
report
enhanc
antibodi
effector
function
contribut
antiebov
activ
use
screen
criteria
mab
produc
lowfucos
cell
line
select
within
week
initi
immun
campaign
select
lead
antibodi
stabli
express
eesyr
cho
cell
line
recombinationmedi
cassett
exchang
eesyr
locu
gene
recombin
eesyr
locu
except
stabl
precis
recombin
monitor
exchang
fluoresc
protein
gene
chromosom
incom
target
vector
us
patent
use
cell
isogen
cho
cell
bank
establish
yield
sever
gram
per
liter
mab
singl
use
bioreactor
data
shown
purifi
protein
avail
vitro
test
approxim
month
immun
largerscal
purifi
lot
use
nhp
studi
avail
approxim
month
later
good
manufactur
practic
gmp
qualiti
antibodi
use
vivo
studi
test
safeti
human
volunt
avail
less
year
initi
immun
campaign
bind
ebov
gp
high
affin
retain
bind
low
ph
crosscompet
surfac
plasma
reson
use
determin
kinet
bind
paramet
interact
recombin
histidinetag
makona
strain
ebov
gp
ectodomain
protein
ebov
ph
test
antibodi
captur
onto
sensor
chip
surfac
via
fc
region
follow
inject
recombin
ebov
gp
k
rang
nm
reflect
highaffin
bind
antibodi
tabl
addit
studi
examin
whether
antibodi
retain
bind
normal
rang
endosom
ph
shown
tabl
mab
display
less
increas
k
valu
ph
indic
ph
bind
gp
still
tight
addit
bind
sgp
measur
antibodi
captur
onto
octet
hqx
sensor
fortebio
immers
nm
solut
ebov
sgp
ebov
gp
irrelev
neg
control
ligand
wherea
mab
bound
ebov
gp
demonstr
specif
bind
sgp
tabl
suggest
bind
within
first
amino
acid
common
region
gp
sgp
two
method
use
demonstr
mab
bind
nonoverlap
epitop
ebov
gp
first
crosscompetit
pair
mab
assess
use
octet
htx
system
captur
ebov
gp
protein
onto
octet
sensor
first
test
antibodi
allow
bind
satur
follow
exposur
second
test
antibodi
possibl
pair
combin
ebovspecif
mab
isotyp
control
test
tabl
assay
format
show
compet
bind
ebov
gp
substanti
whether
antibodi
abl
bind
ebov
gp
simultan
sequentialbind
studi
perform
use
spr
satur
amount
mab
appli
separ
sequenti
step
ebov
gp
sensor
chip
surfac
use
permut
order
antibodi
addit
figur
show
sensorgram
display
sequenti
increas
bind
signal
result
inject
ebov
gp
sensor
chip
follow
inject
control
experi
demonstr
repeat
inject
antibodi
result
addit
bind
signal
indic
bind
site
antibodi
satur
first
inject
data
shown
similar
result
obtain
permut
order
antibodi
inject
figur
demonstr
bind
simultan
ebov
gp
defin
antibodi
bind
site
use
singleparticl
negativestain
electron
microscopi
em
ebov
gp
bound
fab
prepar
mab
imag
use
creat
reconstruct
shown
figur
consist
spr
find
comparison
reconstruct
indic
antibodi
bind
differ
site
gp
molecul
antibodi
figur
purpl
steepest
angl
approach
gp
bind
nearli
perpendicular
viral
surfac
antibodi
bind
within
chalic
structur
near
head
gp
may
partial
contact
glycan
cap
placement
allow
gp
trimer
accommod
fab
despit
tight
cluster
epitop
figur
green
bind
parallel
viral
surfac
outsid
glycan
cap
final
figur
orang
bind
base
gp
protom
function
properti
mab
character
determin
vitro
neutral
abil
vitro
capac
elicit
signal
effector
cell
abil
block
lethal
ebov
diseas
guinea
pig
abil
neutral
lentivir
particl
pseudotyp
makona
strain
ebov
gp
shown
figur
neutral
pseudoviru
particl
half
maxim
inhibitori
concentr
ic
valu
nm
respect
although
neutral
never
exceed
contrast
display
weak
neutral
high
antibodi
concentr
cocktail
antibodi
demonstr
potent
neutral
ic
nm
none
antibodi
block
entri
vsvgpseudotyp
control
particl
indic
activ
specif
ebov
gp
figur
addit
test
antibodi
live
viru
prnt
assay
use
makona
mayinga
guinea
pigadapt
mayinga
kikwit
ebov
strain
tabl
potent
neutral
viru
infect
across
strain
test
valu
nm
strain
wherea
display
signific
neutral
assay
differ
neutral
potenc
consist
publish
data
show
pseudotyp
virus
easili
neutral
wildtyp
virus
probabl
reflect
lesser
amount
gp
present
pseudovirion
effector
function
antibodi
recogn
import
clearanc
mani
viru
type
cellmedi
cytotox
import
clearanc
ebov
diseas
present
unclear
previou
report
indic
adcc
elicit
antibodi
isol
human
survivor
studi
suggest
reduc
fucos
form
nonneutr
mab
efficaci
anim
model
ebov
infect
mab
normal
level
fucos
determin
whether
vitro
properti
antibodi
translat
vivo
activ
evalu
postexposur
therapeut
efficaci
lethal
ebov
challeng
guinea
pig
model
infect
guinea
pig
chosen
use
predict
therapeut
benefit
antibodycocktail
eventu
test
nhp
group
anim
approxim
gram
challeng
target
dose
pfu
guinea
pigadapt
ebov
follow
hour
later
singl
dose
antibodi
placebo
control
guinea
pig
monitor
twice
daili
day
kaplanmei
surviv
curv
cohort
clinic
score
anim
treatment
group
shown
figur
guinea
pig
placebo
group
succumb
ebov
diseas
day
contrast
postchalleng
administr
antibodi
shown
delay
ebov
diseas
symptom
onset
prevent
delay
death
observ
period
potent
neutral
vitro
display
greatest
individu
efficaci
treat
anim
surviv
protect
approxim
infect
anim
wherea
improv
median
surviv
day
anim
eventu
succumb
diseas
clinic
score
indic
delay
onset
diseas
sign
mabtreat
anim
compar
placebo
treatment
addit
surviv
anim
group
display
limit
clinic
sign
infect
studi
show
diseas
model
antibodi
block
infect
neutral
effector
function
via
signal
combin
activ
show
benefit
vivo
administ
monotherapi
taken
togeth
vitro
vivo
result
demonstr
mab
select
differ
bind
function
activ
profil
confer
protect
diseas
lethal
vivo
model
ebov
diseas
rhesu
macaqu
model
ebov
infect
recapitul
key
featur
human
diseas
use
demonstr
therapeut
potenti
independ
studi
design
assess
effect
antibodi
dose
regimen
efficaci
first
studi
show
postinfect
dose
cocktail
administ
mgkg
total
antibodi
result
protect
lethal
diseas
rhesu
macaqu
challeng
target
dose
pfu
kikwit
strain
ebov
intramuscular
inject
random
group
group
control
arm
contain
anim
administ
intraven
placebo
control
group
treatment
arm
contain
anim
administ
cocktail
intraven
mgkg
day
postinfect
anim
monitor
daili
sign
ebov
diseas
shown
figur
placebotr
anim
succumb
ebov
diseas
day
postinfect
contrast
despit
show
diseas
symptom
day
treatment
began
none
anim
receiv
antibodi
cocktail
succumb
diseas
clinic
score
figur
indic
diseas
symptom
treat
anim
also
abrog
treat
anim
show
obviou
sign
diseas
third
dose
cocktail
administ
day
analysi
serum
viral
load
plaqu
assay
figur
indic
treat
anim
undetect
circul
replicationcompet
viru
first
dose
cocktail
bodi
temperatur
record
telemetri
supplement
figur
indic
anim
placebo
group
sustain
fever
supplement
figur
f
red
purpl
dot
persist
succumb
diseas
likewis
antibodi
cocktailtr
anim
exhibit
fever
begin
day
postinfect
howev
contrast
placebo
group
fever
end
anim
day
provid
addit
clinic
measur
indic
anim
recov
day
initi
treatment
third
dose
cocktail
administ
evalu
whether
singledos
regimen
similarli
protect
second
independ
postexposur
treatment
studi
perform
differ
facil
eighteen
rhesu
macaqu
challeng
target
dose
pfu
kikwit
strain
ebov
divid
group
receiv
placebo
control
anim
dose
mgkg
antibodi
mixtur
day
postinfect
anim
dose
mgkg
antibodi
mixtur
day
postinfect
anim
dose
mg
kg
antibodi
mixtur
day
postviru
challeng
anim
monitor
daili
mortal
clinic
symptom
figur
b
previou
studi
placebo
controltr
anim
succumb
ebov
diseas
day
contrast
treatment
result
surviv
anim
treatment
group
despit
find
anim
show
multipl
clinic
sign
diseas
treatment
initi
figur
anim
succumb
infect
mgkg
mgkg
group
anim
surviv
mgkg
group
signific
differ
treatment
arm
indic
fewer
dose
less
total
administ
antibodi
singl
administr
antibodi
cocktail
provid
similar
therapeut
result
previous
observ
mgkg
dose
cocktail
similar
observ
first
studi
combin
clinic
score
placebo
antibodytr
anim
figur
indic
anim
advanc
diseas
control
treatment
major
infect
anim
display
symptom
approxim
day
postinfect
final
viru
load
measur
sera
infect
control
treat
anim
differ
assay
plaqu
assay
detect
infecti
viru
figur
quantit
pcr
detect
presenc
viru
genom
figur
viral
load
studi
confirm
antibodi
treatment
placebo
treatment
control
ebov
infect
reduc
viru
load
fold
show
anim
succumb
ebov
diseas
treat
group
display
viral
genom
copi
number
higher
member
treat
cohort
addit
data
show
similar
level
viru
load
control
treat
anim
regardless
treatment
regimen
third
studi
design
test
singl
treatment
dose
clinic
eas
use
outbreak
set
evalu
minim
efficaci
dose
cocktail
forti
rhesu
macaqu
challeng
divid
group
receiv
placebo
control
anim
mg
kg
anim
mgkg
anim
mgkg
anim
mgkg
anim
antibodi
cocktail
day
postinfect
shown
figur
placebo
controltr
anim
succumb
ebov
diseas
seen
second
studi
despit
clear
diseas
sign
present
administr
mgkg
antibodi
cocktail
result
almost
complet
surviv
infect
anim
anim
addit
singl
treatment
mgkg
result
similar
high
surviv
anim
singl
treatment
mg
kg
led
surviv
anim
nonsignific
differ
compar
higherdos
group
wherea
mgkg
partial
effect
succumb
infect
despit
treatment
durat
fever
figur
extent
temperatur
increas
figur
ident
mgkg
mgkg
group
indic
dose
cocktail
similar
effect
control
fever
comparison
anim
receiv
mgkg
dose
slightli
impair
control
fever
wherea
mgkg
group
display
temperatur
read
similar
placebotr
group
even
though
signific
number
anim
surviv
cohort
thu
singledos
treatment
cocktail
afford
highlevel
dosedepend
postexposur
protect
lethal
ebov
diseas
mgkg
lowest
dose
test
gave
best
control
symptom
catastroph
outbreak
ebov
west
africa
current
outbreak
congo
emphas
need
develop
rapid
systemat
approach
develop
therapeut
treatment
diseas
multipl
class
ebov
diseas
therapeut
rang
small
molecul
inhibitor
act
viral
replic
mab
recogn
viral
protein
describ
human
mab
particularli
appeal
display
predict
pharmacokinet
toler
antipathogen
activ
rapidli
evalu
vitro
base
establish
mechan
action
fulli
human
mab
potent
antivir
activ
gener
rapidli
reliabl
use
platform
base
human
mice
demonstr
present
report
previous
develop
mab
treat
infect
middl
east
respiratori
syndrom
coronaviru
merscov
work
describ
develop
cocktail
antibodi
combin
biolog
activ
improv
efficaci
outcom
reduc
potenti
escap
resist
increas
potenti
util
futur
outbreak
viru
sequenc
evolv
end
select
candid
mab
base
vitro
antibodi
properti
suggest
predict
vivo
efficaci
previou
studi
neutral
nonneutr
antibodi
previous
suggest
efficaci
guinea
pig
nhp
model
assay
establish
measur
neutral
ebov
pseudotyp
well
assay
evalu
abil
trigger
signal
bind
sgp
like
play
role
ebov
pathogenesi
use
approach
gener
pool
antibodi
ebov
gp
select
lead
follow
activ
neutral
ebov
gp
pseudotyp
trigger
signal
bind
sgp
neutral
activ
trigger
high
level
signal
bind
sgp
potent
neutral
ebov
gp
pseudotyp
live
ebov
trigger
signal
bind
sgp
antibodi
purpos
chosen
bind
distinct
epitop
gp
hinder
develop
viral
resist
rapid
screen
select
mab
guinea
pig
model
use
valid
antibodi
signal
neutral
activ
novel
singl
mab
display
neutral
signal
activ
mab
high
level
neutral
activ
delay
prevent
death
model
case
strongli
neutral
antibodi
appear
protect
antibodi
howev
human
fc
may
properli
trigger
guinea
pig
receptor
hard
interpret
contribut
effector
activ
model
analys
perform
use
singleparticl
negativestain
em
provid
wealth
inform
bind
site
mab
studi
reveal
steepest
angl
approach
ebov
gp
bind
perpendicular
viral
surfac
angl
approxim
degre
ebov
gp
trimer
abl
accommod
fab
despit
tight
cluster
epitop
within
chalic
structur
trimer
near
head
gp
area
like
overlap
glycan
cap
appear
bind
even
closer
center
chalic
mab
form
part
zmapp
cocktail
compar
neutral
human
mab
obtain
longterm
human
survivor
ebov
diseas
bind
away
loop
c
bind
site
may
explain
antibodi
neutral
bind
ebov
gp
parallel
viral
surfac
outsid
glycan
cap
posit
could
help
explain
neutral
abil
trigger
final
bind
base
gp
protom
epitop
lie
near
intern
fusion
loop
cathepsin
cleavag
site
similar
neutral
antibodi
deriv
longterm
survivor
recent
crystal
angl
rotat
degre
compar
angl
approach
slightli
upward
viral
surfac
base
bind
site
potent
neutral
activ
may
due
blockad
cathepsin
cleavag
releas
fusion
loop
upon
receptor
bind
similar
mechan
propos
importantli
function
character
structur
data
also
demonstr
cocktail
velocimmun
mab
reflect
divers
mab
produc
wildtyp
mice
mab
obtain
survivor
ebov
diseas
assess
whether
appropri
candid
treatment
ebov
diseas
human
evalu
rhesu
macaqu
model
diseas
work
perform
use
clinic
nonadapt
ebov
isol
replic
mani
key
pathophysiolog
aspect
ebov
infect
man
furthermor
antibodi
mixtur
use
lot
clinicalgrad
materi
undergo
human
test
clinicaltrialsgov
number
use
model
differ
studi
perform
confirm
therapeut
benefit
cocktail
importantli
postexposur
studi
treatment
initi
appear
clinic
sign
diseas
separ
studi
conduct
differ
laboratori
dose
mgkg
singl
infus
mgkg
mgkg
prevent
death
anim
summari
use
velocimmun
mice
gener
cocktail
fulli
human
antibodi
ebov
gp
provid
complementari
mechan
action
reflect
divers
antibodi
isol
convent
method
incorpor
novel
specif
demonstr
highlevel
postexposur
protect
lethal
ebov
diseas
nhp
entir
process
antibodi
gener
select
preclin
evalu
readi
human
test
complet
year
cocktail
current
test
healthi
volunt
prepar
futur
ebov
outbreak
importantli
rapid
isol
fulli
human
mab
previous
report
merscov
ebov
demonstr
use
combin
platform
technolog
current
appli
zika
viru
may
also
applic
futur
emerg
viral
threat
supplementari
materi
avail
journal
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
